Xilio Therapeutics (XLO) Total Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Liabilities across 7 years of filings, most recently posting $90.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $90.9 million, down 2.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.9 million (down 2.23% YoY), and the FY2025 annual result was $119.4 million, up 123.3% from the prior year.
• Total Liabilities came in at $90.9 million for Q1 2026 at Xilio Therapeutics, down from $119.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $141.8 million in Q3 2025 to a low of $24.1 million in Q4 2023.
• The 5-year median for Total Liabilities is $53.5 million (2024), against an average of $60.1 million.
• Across the five-year window, Total Liabilities slumped 72.05% in 2022 and soared 164.12% in 2025, its largest moves.
• Xilio Therapeutics' Total Liabilities stood at $33.5 million in 2022, then slipped by 28.1% to $24.1 million in 2023, then soared by 121.91% to $53.5 million in 2024, then soared by 123.3% to $119.4 million in 2025, then dropped by 23.84% to $90.9 million in 2026.
• The last three Total Liabilities figures came in at $90.9 million (Q1 2026), $119.4 million (Q4 2025), and $141.8 million (Q3 2025), per Business Quant data.